In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals’ Oxymorphone ER, sold under the brand name Opana ER. The proposed class alleges that Endo and would-be generic competitor Impax Laboratories entered an illegal reverse payment agreement under which Endo paid Impax more than $100 million to delay launching a less-expensive generic version of Opana ER.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 06/04/2014
Office
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771